title: HIV vaccine development: would more (public) money bring quicker results?
authors.forename: R
authors.initials: R
authors.lastname: Winsbury
mesh_terms: D000163:Acquired Immunodeficiency Syndrome; D000349:Africa; D017954:Africa South of the Sahara; D000351:Africa, Eastern; D000353:Africa, Southern; D000569:Americas; D003132:Commerce; D019049:Developed Countries; D003906:Developing Countries; D004194:Disease; D004467:Economics; D005060:Europe; D005376:Financial Management; D015658:HIV Infections; D006301:Health Services Needs and Demand; D007221:Industry; D007390:International Agencies; D007630:Kenya; D009656:North America; D009938:Organizations; D012106:Research; D013019:South Africa; D013672:Technology; D006113:United Kingdom; D014480:United Nations; D014481:United States; D014612:Vaccines; D014777:Virus Diseases
chemical_list: D014612:Vaccines
keywords: Acquired Immunodeficiency Syndrome--prevention and control; Africa; Africa South Of The Sahara; Americas; Commerce; Commercial Sector; Developed Countries; Developing Countries; Diseases; Eastern Africa; Economic Factors; English Speaking Africa; Europe; Financial Activities; Funds; Hiv Infections--prevention and control; Industry; International Agencies; Kenya; Macroeconomic Factors; Needs; North America; Northern America; Northern Europe; Organizations; Research And Development; South Africa; Southern Africa; Technology; United Kingdom; United States; Vaccines; Viral Diseases; World; World Bank